摘要
为探讨干扰素治疗小儿慢性丙型肝炎（ＣＨＣ）的疗效、安全性及合适的剂量，对２５例ＣＨＣ患儿进行了干扰素治疗的临床研究，并以１６例ＣＨＣ患儿做为对照。两组在年龄、性别、病程、治疗前症状、体征和实验室检查等方面均有可比性。治疗组分为Ａ、Ｂ、Ｃ３组，Ａ组与Ｂ、Ｃ组采用干扰素剂量不同。２７周疗程结束后，治疗组ＡＬＴ全部恢复正常，ＨＣＶＲＮＡ阴转率Ａ、Ｂ、Ｃ组分别为９０％、１００％、１００％，而对照组仅１２．５％ＡＬＴ恢复正常（χ２＝３３．２１，Ｐ＜０．０１），６．２％ＨＣＶＲＮＡ转阴（χ２＝３３．２８，Ｐ＜０．０１）。干扰素治疗组未见严重不良反应。提示干扰素治疗小儿ＣＨＣ疗效较好，且安全，尤以１００万Ｕ／ｄ连续肌内注射２７周疗效更佳。
Thisstudywasundertakentoevaluatetherapeuticefects,safetyandappropriatedosageofinterferonα-2bintreatmentofchronicviralhepatitisC(CHC)inchildren.Totaly41chil-dren(2to12yearsofage)withCHCwereinvolvedinthisstudy;althepatientswerepositiveforhepatitisCvirus(HCV)RNAandhadelevatedALTlevelforatleast6months.Thepatientsweredividedinto4groups:groupAcases(n=10)weretreatedwithI.M.interferon106IU/dayfor4weeksandthenwiththesamedose,3timesaweek,for23weeks;groupBcases(n=10)weretreatedwiththesamedrug,I.M.,106units/day,for27weeks;groupCcases(n=5)whohadco-infectionwithHCVandhepatitisBvirusweretreatedwiththesameregimenasusedforgroupB.Theremaining16patients(controlgroup)withCHCweretreatedwithaherbalmedicine.ThegroupsA,Bandcontrolcaseswerecomparableclinicalyandinlaboratoryfindings.Theresultsofthestudyshowedthatafterthetreatment,theALTlevelreturnedtonormalinalthecasesofgroupsA,BandCbutinonly2ofthecontrolcases(χ2=33.21,P<0.01).HCVRNAbecameneg-ativein9/10ofgroupAandinalthecasesofgroupB(10/10)andC(5/5)whileinonly1/16ofthecontrolcases(χ2=33.28,P<0.01).Nosevereadverseefectswereobservedintheinterferon-treatedgroups.Theseresultssuggestthatinterferonα-2b,whengivenatadoseof106units/dayfor27weeks,maybepracticalandsafeintreatmentofCHCinchildren.
出处
《中华儿科杂志》
CAS
CSCD
北大核心
1996年第6期397-400,共4页
Chinese Journal of Pediatrics
